![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MK Ritke, JM Rusnak, JS Lazo, WP Allan, C Dive, S Heer and JC Yalowich
Department of Pharmacology, University of Pittsburgh School of Medicine, Pennsylvania 15261.
Etoposide (VP-16) is one of several DNA-damaging agents that induce subcellular structural changes associated with apoptosis. VP-16 exerts its DNA-damaging and cytotoxic effects subsequent to interference with DNA topoisomerase II activity. VP-16 also stimulates c-jun and c-fos mRNA expression in some cell lines, including human leukemia K562 and HL-60 cells. To compare the temporal relationship between drug-induced c-jun expression and apoptosis, we examined cell morphology, cell viability, DNA integrity, and c-jun induction during VP-16 treatment of K562 and HL-60 cells. VP-16 (10 microM)-induced internucleosomal DNA damage and nuclear fragmentation were readily apparent within 6 hr in HL-60 cells but were absent in K562 cells treated for up to 24 hr. Some internucleosomal DNA damage was observed in K562 cells but only after treatment with 100 microM VP-16 for 24 hr. In contrast, VP-16-induced DNA single-strand breaks, VP-16-induced topoisomerase II/DNA covalent complex formation, and VP-16-mediated growth inhibition were similar in K562 and HL-60 cells. Also, the time course of VP-16-induced c-jun mRNA expression was comparable for both K562 and HL-60 cell lines. Western blot analysis of whole-cell lysates showed that Bcl-2 protein levels were 13-fold greater in HL-60 cells than in K562 cells. Thus, the resistance of VP-16-treated K562 cells to apoptosis was not attributable to protection by Bcl-2. Furthermore, the relatively high levels of Bcl-2 in HL-60 cells were not sufficient to protect these cells against apoptosis. Together, our results indicate that the temporal coupling of VP-16-induced DNA damage, c-jun expression, and apoptosis is cell type specific and suggest that different signaling pathways for apoptosis are operating in these two human leukemia cell lines.
This article has been cited by other articles:
|
|
 |
|
  M.-G. Song, S.-M. Gao, K.-M. Du, M. Xu, Y. Yu, Y.-H. Zhou, Q. Wang, Z. Chen, Y.-S. Zhu, and G.-Q. Chen Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase C{delta}-dependent mechanisms Blood, May 1, 2005; 105(9): 3714 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xiao, T.-K. Li, J.-M. Yang, and L. F. Liu Acidic pH induces topoisomerase II-mediated DNA damage PNAS, April 29, 2003; 100(9): 5205 - 5210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Chung, S.-G. Hwang, P. Nguyen, S. Lee, J.-S. Kim, J. W. Kim, P. A. Henkart, D. P. Bottaro, L. Soon, P. Bonvini, et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta -catenin Blood, July 18, 2002; 100(3): 982 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. U. Kurz, S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich, and D. J. Kroll The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines Mol. Cancer Ther., December 1, 2001; 1(2): 121 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Hasinoff, M. E. Abram, N. Barnabé, T. Khélifa, W. P. Allan, and J. C. Yalowich The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells Mol. Pharmacol., March 1, 2001; 59(3): 453 - 461. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Shimamoto, A. Tomoda, R. Ishida, and K. Ohyashiki Antitumor Effects of a Novel Phenoxazine Derivative on Human Leukemia Cell Lines in Vitro and in Vivo Clin. Cancer Res., March 1, 2001; 7(3): 704 - 708. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. D. Jarvis, C. R. Johnson, F. A. Fornari, J. S. Park, P. Dent, and S. Grant Evidence That the Apoptotic Actions of Etoposide Are Independent of c-Jun/Activating Protein-1-Mediated Transregulation J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1384 - 1392. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Sabourin, J. A. W. Byl, S. E. Hannah, J. L. Nitiss, and N. Osheroff A Mutant Yeast Topoisomerase II (top2G437S) with Differential Sensitivity to Anticancer Drugs in the Presence and Absence of ATP J. Biol. Chem., October 30, 1998; 273(44): 29086 - 29092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Murray and A. P. Fields Atypical Protein Kinase C iota Protects Human Leukemia Cells against Drug-induced Apoptosis J. Biol. Chem., October 31, 1997; 272(44): 27521 - 27524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hay, J. Lemonnier, O. Fromigue, and P. J. Marie Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway J. Biol. Chem., July 27, 2001; 276(31): 29028 - 29036. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
